Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2011 / Cilt: 37 - Sayı: 3

Changes in patients' quality of life folowing treatment of localized and metastatic prostate cancer

Lokalize ve metastatik prostat kanserli hastalarda tedavi sonrası yaşam kalitesi değişiklikleri

Pages
184–190
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although quality of life of metastatic prostate cancer patients was initially worse than that of localized prostate cancer patients, improvement of quality of life in patients with metastatic cancer was more obvious.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to evaluate the change of quality of life of patients with localized and metastatic prostate cancer after treatment.
📊
Key Findings & Data:Materials and methods: Twenty-eight patients (mean age 62.45±7.11 years) who were treated with radical prostatectomy and 14 patients (mean age 69.94±8.39 years) who were treated with orchioectomy between December 2007 and June 2010 were included in the study.
💡
Conclusion & Impact:Although quality of life of metastatic prostate cancer patients was initially worse than that of localized prostate cancer patients, improvement of quality of life in patients with metastatic cancer was more obvious.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to evaluate the change of quality of life of patients with localized and metastatic prostate cancer after treatment. Materials and methods: Twenty-eight patients (mean age 62.45±7.11 years) who were treated with radical prostatectomy and 14 patients (mean age 69.94±8.39 years) who were treated with orchioectomy between December 2007 and June 2010 were included in the study. Patients were asked to complete EORTC QOL-30 instrument before (T0) and 1st (T1), 3rd (T2), 6th (T3), and 12th (T4) months after the treatment. QOL-C30 scores were calculated and converted to 0-100 scale. Score changes of QOL-C30 were the change in scores of related time period from basal score (T1-T0, T2-T0, T3-T0, and T4-T0). Optimum time to evaluate quality of life was defined by determining the score which was closest to the basal score. In addition, the affected quality of life parameters were determined. Results: The mostly affected parameter was the social functioning in radical prostatectomy group. Quality of life got worse in each time period. Total quality of life was the most affected parameter in orchioectomy group. Quality of life significantly increased in first month measurement, and this increase continued in 3rd, 6th, and 12th months. In both groups, quality of life deteriorated from baseline mostly in 1st month after the treatment. Quality of life was closest to the basal values in 12th month measurements. Conclusion: Patients’ quality of life should be assessed at 3rd month following treatment of localized and metastatic prostate cancer. Although quality of life of metastatic prostate cancer patients was initially worse than that of localized prostate cancer patients, improvement of quality of life in patients with metastatic cancer was more obvious.

Özet

Amaç: Bu çalışmada lokalize ve metastatik prostat kanserli hastaların tedavi sonrası yaşam kalitesinin zamanla değişiminin değerlendirilmesi amaçlandı. Gereç ve yöntem: Aralık 2007 ile Haziran 2010 tarihleri arasında radikal prostatektomi yapılan 28 hasta (ortalama yaş 62.45±7.11) ve cerrahi orşioektomi yapılan 14 hasta (ortalama yaş 69.94±8.39) çalışmaya dahil edildi. Hastalardan EORTC QOL-C30 (version 3.0) sorgulama formunu tedavi öncesi (T0), tedavinin 1. ayı (T1), 3. ayı (T2), 6. ayı (T3) ve 12. ayında (T4) doldurmaları istendi. QOL-C30 skorlaması yapıldı ve tüm skorlar 0-100 arası değerlere çevrildi. QOL-C30 skor değişiklikleri değişik zaman periyotlarında bazal değerden sapmanın hesaplanmasıyla bulundu (T1-T0, T2-T0, T3-T0 ve T4-T0). Bazal değere en yakın sonuçların elde edildiği dönem tespit edilerek hayat kalitesini ölçmek için en uygun zaman belirlendi. Ayrıca etkilenen hayat kalitesi parametreleri tespit edildi. Bulgular: Radikal prostatektomi grubunda en çok etkilenen parametre sosyal işlev parametresiydi. Yaşam kalitesinin ölçüldüğü her zaman aralığında kötüye gidiş görüldü. Orşioektomi yapılan grupta ise genel yaşam kalitesi parametresi en fazla etkilenen parametreydi. İlk ayda ölçülen yaşam kalitesinde anlamlı bir artış görüldü ve bu artış 3., 6. ve 12. ayda devam etti. Her iki grupta da ölçümlerin yapıldığı ilk ay, hayat kalitesi değerlendirmesinde bazal değerlerden en fazla sapma olan dönemdi. Bazal değerlere en çok 12. ayda yaklaşıldı. Sonuç: Hayat kalitesi değerlendirilmesi lokalize ve metastatik prostat kanserli hastalarda tedavi sonrası 3. ayda yapılmalıdır. Metastatik prostat kanseri olan hastaların yaşam kalitesi lokalize prostat kanseri olan hastalara göre başlangıçta daha kötü olmasına karşın tedaviden sonra yaşam kalitesinde düzelme bu grupta daha fazladır.

🔖

Cite This Article

FAYDACI, G., METİN, M., ERYILDIRIM, B., TARHAN, F., TUNCER, M., ÖZGÜL, A. (2011). Changes in patients' quality of life folowing treatment of localized and metastatic prostate cancer. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 37 - Sayı: 3, 184–190. https://ajindex.com/articles/328665

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29
  2. Wingo PA, Tong T, Bolden S. Cancer Statistics, 1995. CA Cancer J Clin 1995; 45: 8-30
  3. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatmend of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76
  4. Fayers P, Aaronson N, Bjordal K, Curran D, Groenvold M. EORTC QLQ-C30 Skoring Manual. Brussels, Belgium, Quality of Life Unit, EORTC Data Center, 1995
  5. Rodrigues G, Bezjak A, Osoba D, Catton P, Tsuji D, Taylor D, et al. The relationship of changes in EORTC QLQ-C30 scores to rating on the Subjective Significance Questionare in men with localized prostate cancer. Qual Life Res 2004; 12: 1235-46
  6. Quek ML, Penson DF. Quality of life in patients with localized prostate cancer. Urol Oncol 2005; 23: 208-15
  7. Higginson IJ, Carr AJ. The clinical utility of quality of life measures. Quality of Life. London: BMF Publishing Group; 2003. p. 63-78
  8. Lee WR, McQuellon RP, Harris-Henderson K, Case LD, McCullough DL. A preliminary analysis of heart related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 77-81
  9. McCammar KA, Kolm P, Main B, Schellhammer PF. Comparative quality of life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999; 54: 509-16
  10. Bacon CG, Giovanucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166: 1804-10
  11. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993; 2: 221-6
  12. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44
  13. Davison BJ, So AI, Goldenberg SL. Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer. BJU Int 2007; 100: 780-5
  14. You D, Jeong IG, Kim SW, Chung BH, Cho JS, Lee HM, et al. Impacts of leuprolide acetate on quality of life in patients with prostate cancer. A prospective multicenter study. Scand J Urol Ne